Generic Name and Formulations:
Ethosuximide 250mg; caps.
Indications for ZARONTIN:
Initially: 500mg daily. Increase every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses.
<3yrs: not established. 3–6yrs: initially 250mg daily. >6yrs: initially 500mg daily. Increase both every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses. Usual maintenance: 20mg/kg/day in divided doses.
Impaired hepatic or renal function. May precipitate tonic-clonic seizures. Discontinue at 1st sign of rash; consider alternative therapy if signs/symptoms of Stevens-Johnson syndrome occurs. Evaluate immediately if signs/symptoms of DRESS/multi-organ hypersensitivity develop; discontinue if no alternative etiology. Monitor for depression, suicidal ideation, unusual changes in mood/behavior. Monitor CBCs, kidney and liver function periodically. Change dose gradually. Pregnancy. Nursing mothers: not recommended.
Monitor phenytoin, phenobarbital, valproic acid, other AEDs.
Blood dyscrasias, drowsiness, ataxia, dizziness, headache, GI upset, CNS and psychiatric effects, rash (may be fatal), SLE, DRESS, gingival hyperplasia.
Caps, syrup (YES)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC